Chemotherapy and treatment course
| Induction course . | Value . |
|---|---|
| Asp in induction course, n (%) | 233 (100) |
| Asp formulation | |
| PEG-Asp | 229 (98.3) |
| Other Asp formulation | 3 (1.3) |
| Not available | 1 (0.4) |
| Route of administration | |
| IV | 205 (88.0) |
| Intramuscular | 25 (10.7) |
| Subcutaneous | 1 (0.4) |
| Not available | 2 (0.9) |
| No. of doses of Asp | |
| 1 | 216 (92.7) |
| 2 | 15 (6.4) |
| Not available | 2 (0.9) |
| Dose of Asp,∗ IU/m2 | |
| 1000 | 41 (17.6) |
| 2000 | 41 (17.6) |
| 2500 | 141 (60.5) |
| Not available | 10 (4.3) |
| Dose of Asp capped | |
| Yes | 22 (9.4) |
| Dose cap 2000 IU | 1 |
| Dose cap 3750 IU | 18 |
| Other | 3 |
| No | 173 (74.2) |
| Not available | 38 (16.3) |
| Induction chemotherapy regimen, n (%) | |
| CALGB 10403 | 78 (33.5) |
| Linker regimen | 42 (18.0) |
| Chemotherapy + TKI | 25 (10.7) |
| ECOG E1910 | 18 (7.7) |
| CALGB 8811 (Larson regimen) | 17 (7.3) |
| COG AALL 0232 | 7 (3.0) |
| COG AALL 1131 | 9 (3.9) |
| COG AALL 1231 | 6 (2.6) |
| Other | 29 (12.4) |
| Not available | 2 (0.9) |
| Steroid with induction, n (%) | |
| Dexamethasone | 92 (39.5) |
| Prednisone | 110 (47.2) |
| Methylprednisolone | 2 (0.9) |
| Unknown steroid type | 8 (3.4) |
| None or not available | 21 (9.4) |
| Central catheters in induction, n (%) | |
| No. of central catheters | |
| 0 | 6 (2.6) |
| 1 | 171 (73.4) |
| ≥2 | 44 (18.9) |
| Not available | 12 (5.2) |
| Type of central catheters | |
| PICC | 98 (42.1) |
| CVC† | 101 (43.3) |
| Port | 15 (6.4) |
| None or not available | 19 (8.2) |
| Thrombosis and bleeding prophylaxis, n (%) | |
| No. of patients monitored with AT levels | 96 (41.2) |
| No. of patients receiving AT repletion | 58 (24.9) |
| No. of patients receiving prophylactic anticoagulation | 41 (17.6) |
| Heparin | 5 (12.2) |
| Enoxaparin | 36 (87.8) |
| Duration of anticoagulation, median (range), d | 10 (6.5-18.5) |
| No. of patients receiving AT repletion and prophylactic anticoagulation | 21 (9.0) |
| No. of patients receiving therapeutic anticoagulation | 8 (3.4) |
| No. of patients receiving cryoprecipitate | 145 (62.2) |
| Fibrinogen trigger for cryoprecipitate transfusion, mg/dL | |
| <50 | 3 (2.1) |
| 50-99 | 116 (80.0) |
| 100-150 | 25 (10.7) |
| No. of patients receiving FFP | 22 (9.4) |
| Laboratory values, median (range) | |
| Platelet nadir, ×109/L | 12 (7-46) |
| Fibrinogen nadir, mg/dL | 90 (72-124) |
| AT nadir, % | 50.5 (44-58.5) |
| Induction course . | Value . |
|---|---|
| Asp in induction course, n (%) | 233 (100) |
| Asp formulation | |
| PEG-Asp | 229 (98.3) |
| Other Asp formulation | 3 (1.3) |
| Not available | 1 (0.4) |
| Route of administration | |
| IV | 205 (88.0) |
| Intramuscular | 25 (10.7) |
| Subcutaneous | 1 (0.4) |
| Not available | 2 (0.9) |
| No. of doses of Asp | |
| 1 | 216 (92.7) |
| 2 | 15 (6.4) |
| Not available | 2 (0.9) |
| Dose of Asp,∗ IU/m2 | |
| 1000 | 41 (17.6) |
| 2000 | 41 (17.6) |
| 2500 | 141 (60.5) |
| Not available | 10 (4.3) |
| Dose of Asp capped | |
| Yes | 22 (9.4) |
| Dose cap 2000 IU | 1 |
| Dose cap 3750 IU | 18 |
| Other | 3 |
| No | 173 (74.2) |
| Not available | 38 (16.3) |
| Induction chemotherapy regimen, n (%) | |
| CALGB 10403 | 78 (33.5) |
| Linker regimen | 42 (18.0) |
| Chemotherapy + TKI | 25 (10.7) |
| ECOG E1910 | 18 (7.7) |
| CALGB 8811 (Larson regimen) | 17 (7.3) |
| COG AALL 0232 | 7 (3.0) |
| COG AALL 1131 | 9 (3.9) |
| COG AALL 1231 | 6 (2.6) |
| Other | 29 (12.4) |
| Not available | 2 (0.9) |
| Steroid with induction, n (%) | |
| Dexamethasone | 92 (39.5) |
| Prednisone | 110 (47.2) |
| Methylprednisolone | 2 (0.9) |
| Unknown steroid type | 8 (3.4) |
| None or not available | 21 (9.4) |
| Central catheters in induction, n (%) | |
| No. of central catheters | |
| 0 | 6 (2.6) |
| 1 | 171 (73.4) |
| ≥2 | 44 (18.9) |
| Not available | 12 (5.2) |
| Type of central catheters | |
| PICC | 98 (42.1) |
| CVC† | 101 (43.3) |
| Port | 15 (6.4) |
| None or not available | 19 (8.2) |
| Thrombosis and bleeding prophylaxis, n (%) | |
| No. of patients monitored with AT levels | 96 (41.2) |
| No. of patients receiving AT repletion | 58 (24.9) |
| No. of patients receiving prophylactic anticoagulation | 41 (17.6) |
| Heparin | 5 (12.2) |
| Enoxaparin | 36 (87.8) |
| Duration of anticoagulation, median (range), d | 10 (6.5-18.5) |
| No. of patients receiving AT repletion and prophylactic anticoagulation | 21 (9.0) |
| No. of patients receiving therapeutic anticoagulation | 8 (3.4) |
| No. of patients receiving cryoprecipitate | 145 (62.2) |
| Fibrinogen trigger for cryoprecipitate transfusion, mg/dL | |
| <50 | 3 (2.1) |
| 50-99 | 116 (80.0) |
| 100-150 | 25 (10.7) |
| No. of patients receiving FFP | 22 (9.4) |
| Laboratory values, median (range) | |
| Platelet nadir, ×109/L | 12 (7-46) |
| Fibrinogen nadir, mg/dL | 90 (72-124) |
| AT nadir, % | 50.5 (44-58.5) |